BTC Health Limited (ASX:BTC) has disclosed that Arna Pharma Pty Ltd, the sole manufacturer of Bronchitol® and Aridol®, was placed into voluntary administration on 7 September 2026 following the appointment of administrators by Arna Pharma's board, creating uncertainty over the continued supply of both TGA-registered products distributed exclusively by BTC Health's wholly owned subsidiary, BTC Pharma Pty Ltd.
Key Points
- Arna Pharma Pty Ltd entered voluntary administration on 7 September 2026 after its board appointed administrators.
- BTC Pharma currently holds approximately eight months of Bronchitol® stock and less than one month of Aridol® stock.
- Aridol® and Bronchitol® generated combined sales of $1.1 million in FY2026; without further supply, BTC Health expects sales of up to $0.5 million in FY2027.
- BTC Health stated it cannot verify Arna Pharma's intention to recapitalise and gives no assurance that manufacture or supply will resume.
- Neither BTC Pharma nor BTC Health is a shareholder, lender, guarantor or related party of Arna Pharma, with no directors in common.
Arna Pharma Administration and Manufacturing Arrangements
Arna Pharma manufactures both Bronchitol® and Aridol® exclusively at its Sydney facility. BTC Pharma, a wholly owned subsidiary of BTC Health, holds the Australian sponsorship and exclusive distribution rights for both products, which are TGA-registered. Bronchitol® is also listed on the Pharmaceutical Benefits Scheme. According to the filing, BTC Pharma is a customer of Arna Pharma only, and the group has no exposure to the administration beyond ordinary supply arrangements, with no shared directors, shareholding, lending or guarantee relationships between the entities.
Current Stock Holdings and Supply Uncertainty
As disclosed in the filing, BTC Pharma currently holds approximately eight months of Bronchitol® stock and less than one month of Aridol® stock. Arna Pharma has stated its intention to recapitalise the business and maintain continuity of supply. BTC Health disclosed it cannot verify that position and gives no assurance that manufacture or supply will resume. BTC Pharma is engaging with the administrators and, in its capacity as sponsor of both products, with the Therapeutic Goods Administration and the Department of Health, Disability and Ageing regarding continuity of supply.
Financial Impact on FY2026 and FY2027 Sales
The filing states that Aridol® and Bronchitol® generated combined sales of $1.1 million in FY2026. BTC Health disclosed that, without further supply of these products, it expects sales of Aridol® and Bronchitol® to be up to $0.5 million in FY2027. BTC Health said it will keep the market informed of material developments as they arise. The filing was authorised for release by the Board of BTC Health Limited and was dated 8 September 2026.





Please wait processing your request...